It is the largest program of its kind in the Philadelphia region and one of the largest on the East Coast. It is devoted to investigating new and evolving therapies and comprehensive management of patients with primary neoplasms of the nervous system and all neurological complications of cancer.
Members of the program co-operate with several basic science groups at the Kimmel Cancer Center on early translational therapeutics. We are pioneering the development of antisense targeting of the IGF-1 receptor as treatment of malignant gliomas. The group is also a leader in co-operative group therapies that are developed by national cancer study consortia, many pioneered by Jefferson clinicians.
